Evidence map›Paper›PMID 36440637›Full record

ArticleEpidemiology and infection2022

Eligibility criteria

Feline de la Court, Anders Boyd, Udi Davidovich, Elske Hoornenborg, Maarten F Schim Van Der Loeff, Henry J C De Vries, Daphne A Van Wees, Birgit H B Van Benthem, Maria Xiridou, Amy Matser and 1 more

Open access · goldAbstract read
In one paragraph

Article in Epidemiology and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Feline de la CourtDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0001-6539-9364
Anders BoydDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Udi DavidovichDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Elske HoornenborgDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Maarten F Schim Van Der LoeffDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Henry J C De VriesDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Daphne A Van WeesCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Birgit H B Van BenthemCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Maria XiridouCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Amy MatserDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Maria PrinsDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
GGD Amsterdam · NLNational Institute for Public Health and the Environment · NLStichting HIV Monitoring · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To reappraise pre-exposure prophylaxis (PrEP) eligibility criteria towards the men who have sex with men (MSM) with highest HIV-risk, we assessed PrEP need (i.e. HIV-risk) using Amsterdam Cohort Studies data from 2011-2017 for all non-PrEP using MSM. Outcomes were incident HIV-infection and newly-diagnosed anal STI. Determinants were current PrEP eligibility criteria (anal STI and condomless sex (CAS)) and additional determinants (age, education, group sex, alcohol use during sex and chemsex). We used targeted maximum likelihood estimation (TMLE) to estimate the relative risk (RR) and 95% confidence intervals (CI) of determinants on outcomes, and calculated population attributable fractions (PAFs) with 95% CI using RRs from TMLE. Among 810 included MSM, 22 HIV-infections and 436 anal STIs (

Indexed as

HIV InfectionsSexual and Gender MinoritiesSexually Transmitted DiseasesHomosexuality, MaleHumansMaleNetherlandsChemsexHIV/AIDSmen who have sex with men (MSM)pre-exposure prophylaxis (PrEP)sexually transmitted infections (STIs)

Identifiers

PMID36440637
PMCPMC9987018
OpenAlexW4308588624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.